Audit: QRS - Kylo-11 for Health & Longevity

Audit conducted on 29/08/2026 07:26 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Each protocol cell, time cell, benefit, risk, gate item, marker row and cadence sentence traces to a specific ER passage (ER lines 158, 210, 216-242, 260-281, 303-323, 356, 382-403).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“severity caution, theoretical” (caution item 3) mirrors ER line 264; at-a-glance “remains unknown” mirrors ER Conclusion; time_2_sub retains “From the class pattern and the phase 2 endpoint window”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications and interaction severities carry the ER’s own force; no upgrade or downgrade found.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and interactions come only from ER Key Interactions & Contraindications; benefits from Expected Benefits; risks from Potential Risks & Side Effects; no cross-category migration.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT identifiers, no author names in the QRS; every drug name in the interaction gate appears in the ER for the same interaction bullet.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Reserved, evidence-bounded register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and dose ranges paired with plain-language framing; the sheet states what is known and what is not without discouraging language.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive throughout; no imperatives directed at a person.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommended” or equivalent anywhere in the body content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and monitoring cells report what the trials did and measured, not what to do.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the monitoring table and decision gates where they are the measured quantity; at-a-glance is fully plain.
2.8	Information is presented in a concise and very compact manner	🟢	Every entry is a trimmed one-liner; no elaborations carried over.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan; no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional targets (Lp(a) below 30 nmol/L, apoB below 80 mg/dL, ALT below 25 U/L) rather than conventional lab flags.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Baseline cadence of two platform-matched Lp(a) draws four weeks apart and a nine-marker panel assumes exactly that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified or general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance leads with the unwithdrawable twelve-month effect and trial-only access — the two facts that decide the question for a proactive adult.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“subcutaneous injection”, “adverse”, “hepatic impairment”, “malignancy” used; no colloquial substitutes found.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and column headers match the template byte-for-byte (QRS lines 446, 492, 540, 569, 592, 627, 652, 656-658, 796).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	65 spans present: all 34 fixed-name spans plus 9×3 marker spans and 4 qualitative spans expanded from the template’s marker_# / qualitative_item_# rows.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" are untouched; a full diff against the template shows the head, CSS block, footer and disclaimer are byte-identical.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Trial dosing schedule”, “Single versus split dosing”, “Baseline biomarker gate” are the ER’s bold labels verbatim (ER lines 303, 315, 323); interaction labels likewise (ER lines 260-270).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names match the ER monitoring table verbatim; protocol and interaction labels match their ER bullets.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; tiers carry only bold text labels and CSS colour.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every entry is condensed to its shortest faithful form (trailing rationale, consequences and citations stripped); no section was extended with ER prose.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2-14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- line 3, closing --- line 13; the descriptive text on line 2 precedes the opener.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: kylo_11_2026-0829-0505_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0829-0649.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: kylo_11_2026-0829-0505_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Kylo-11 for Health & Longevity - Quick Reference Sheet, with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Kylo-11 for Health & Longevity, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/29/2026, correctly derived from 2026-0829-0649.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; no extra elements.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 429-435: what it is, the duration claim, the unknown outcome, and the access constraint.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Gene-silencing injection (ER 36, 429); diet and standard drugs barely move it (ER 36, 429); deep lowering held ~1 year (ER 158, 210); outcome unknown (ER 431); trial-only access (ER 345, 431).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“inherited cholesterol-carrying blood particle” replaces lipoprotein(a); no acronyms, no drug-class names.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, NCT number, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	“lowers it deeply” carries no percentage or statistic.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the ER’s “Populations who should avoid Kylo-11” list (ER lines 274-281).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER bullets are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight discrete <li> elements inside the stop_items span (QRS lines 571-588).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing clauses stripped: “— the compound is not approved for supply in any jurisdiction” and “, given hepatocyte-directed delivery” both removed.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 5 years”, “(Child-Pugh class C)”, “class III or IV”, “below 30%”, “160/100 mmHg”, “stage 1 prostate carcinoma” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to ER lines 260-270.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Six interaction bullets carried; no overlap with the eight contraindication entries.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Six discrete <li> elements inside the caution_items span (QRS lines 594-618).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Consequence:” clause is stripped; only the label, drug list and severity remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All six drug lists and all six severity classes (“none”, “monitor”, “caution, theoretical”, “none identified”, “monitor”, “caution”) retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names six such interactions, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to bullets in ER Therapeutic Protocol (lines 303, 315, 323).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and route, single-versus-split dosing, and the baseline eligibility threshold are the three decision-bearing bullets; the remaining bullets are background, competing approaches, or explicit non-considerations.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct actionable aspects, and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive ER-derived content (QRS lines 450-487).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Onset (2-4 weeks), nadir (weeks 8-16) and persistence (48 weeks) — the only three timing facts the ER carries (ER lines 158, 356).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	All three attach to the ER’s single Medium-tier benefit (deep, sustained Lp(a) lowering) and run in the order the effect unfolds.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects are available and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content (QRS lines 498-532).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER line 356), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Entries reproduce the ER benefit subheadings at lines 156, 164, 172, 176, 180.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (QRS lines 542-562).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The “Magnitude:” figures (53-97%, 208 nmol/L) and the trial/funding detail are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit entry; the ER’s “(LDL)” gloss and citations are dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier benefit (line 152), and benefits_high carries style="display: none" with no empty-state text (QRS line 542).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Entries reproduce the ER risk subheadings at lines 208, 216, 222, 228, 236, 240.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (QRS lines 629-646).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 2.6%/4.7% injection-site rates and the “no antidote” rationale are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk entry; the ER’s ALT/AST gloss and citations are dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier risk (line 204), and risks_high carries style="display: none" with no empty-state text (QRS line 629).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker names, targets and reasons all trace to the ER biomarker table (ER lines 388-396).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER rows present: Lp(a), apolipoprotein B, LDL cholesterol, ALT/AST, total bilirubin, eGFR, hs-CRP, HbA1c, platelet count.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 785-790 condense ER lines 382 and 384: baseline pairing, liver enzymes at 4 and 12 weeks, Lp(a) at 12 weeks, then 6 and 12 months and annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All four items map to the ER’s qualitative marker list (ER lines 400-403).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All four present: injection-site comfort, energy and exertional tolerance, sleep quality and general wellbeing, confidence in the plan.

Issues 29/08/2026 07:26

Pass rate 100.00%. No issues found.

Issues 29/08/2026 07:17

1. 1.2 — Cautious hedges dropped in Monitoring: marker_8_why (line 764) states “Watches the metabolic signal at very low Lp(a)” where the ER (line 395) writes “Watches the speculative metabolic signal attached to very low Lp(a)”, and marker_9_why (line 777) states “Screens for platelet decline in nucleic-acid drugs” where the ER (line 396) writes “Screens for the platelet decline seen with some nucleic-acid drug classes”.

Fixes 29/08/2026 07:17

1. 1.2 — Cautious hedges restored in Monitoring: marker_8_why changed from “Watches the metabolic signal at very low Lp(a)” to “Watches the speculative metabolic signal at very low Lp(a)”, and marker_9_why from “Screens for platelet decline in nucleic-acid drugs” to “Screens for platelet decline seen with some nucleic-acid drug classes”, matching the ER’s hedged wording.

Issues 29/08/2026 07:09

1. 4.2 / 4.3 — Key Interactions labels not verbatim: Four of the six caution-item bold labels are abbreviated or paraphrased rather than taken verbatim from the ER: “Prescription lipid drugs” → “Lipid drugs” (QRS line 596, ER line 260), “Anticoagulants and antiplatelets” → “Anticoagulants, antiplatelets” (QRS line 603, ER line 264), “Other CYP-metabolized medicines” → “CYP-metabolized medicines” (QRS line 607, ER line 266), and “Supplements that also lower Lp(a)” → “Supplements lowering Lp(a)” (QRS line 611, ER line 268).

Fixes 29/08/2026 07:09

1. 4.2 / 4.3 — Key Interactions labels restored verbatim: Restored the four paraphrased caution-item bold labels to the ER’s own wording — “Lipid drugs” → “Prescription lipid drugs”, “Anticoagulants, antiplatelets” → “Anticoagulants and antiplatelets”, “CYP-metabolized medicines” → “Other CYP-metabolized medicines”, and “Supplements lowering Lp(a)” → “Supplements that also lower Lp(a)”.

Issues 29/08/2026 07:04

1. 4.5 — Sheet renders over two A4 pages: The QRS body measures roughly 2090px against the ~1032px of usable height an A4 print page provides, so it spills onto a second page; the Monitoring card (lines 657–796), the decision gates (lines 568–625), the Protocol sub-texts (lines 456–535) and the Qualitative items (lines 803–827) each carry more wrapped lines than the per-section budget allows.

Fixes 29/08/2026 07:04

1. 4.5 — One-page budget condensation: Condensed the four over-budget regions without dropping any mandated content — the nine Monitoring why and target cells were shortened to single lines (e.g. “Screens for the platelet decline seen with some nucleic-acid drug classes” → “Screens for platelet decline in nucleic-acid drugs”), the cadence paragraph was tightened, the eight contraindications and six interaction items were trimmed while keeping every threshold, severity class and named example drug, the three Protocol and three Time-to-effect sub-texts each lost a wrapped line, and the four Qualitative items were reduced to one line apiece.

Issues 29/08/2026 06:57

1. 1.1 / 9.5 — Coenzyme Q10 miscategorized: The Key Interactions item at lines 613-614 lists coenzyme Q10 inside “Supplements that also lower Lp(a)”, but the ER (line 268) names it only “as a neutral comparator”; trimming that qualifier turns a stated non-effect into a claimed Lp(a)-lowering effect.
2. 8.5 — Breast carcinoma staging term dropped: The malignancy contraindication at lines 585-586 reads “cervical or breast carcinoma in situ” where the ER (line 279) specifies “breast ductal carcinoma in situ”, broadening the exception beyond what the ER supports.

Fixes 29/08/2026 06:57

1. 1.1 / 9.5 — Coenzyme Q10 miscategorized: Restored the ER’s qualifier in the Key Interactions supplement item, changing “omega-3 fatty acids, coenzyme Q10” to “omega-3 fatty acids; coenzyme Q10 as a neutral comparator” so it is no longer presented as an Lp(a)-lowering supplement.
2. 8.5 — Breast carcinoma staging term dropped: Restored the ER’s staging wording in the malignancy contraindication, changing “cervical or breast carcinoma in situ” to “cervical carcinoma in situ, breast ductal carcinoma in situ”.